IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11318215 B1

PDFFull Text
Date of Patent:
May. 03, 2022

Filed:

Feb. 28, 2014

Composition for gene delivery comprising chitosan and liquid crystal formation material

Applicant:

Chong Kun Dang Pharmaceutical Corp., Seoul, KR;

Inventors:

Ho Young Hwang, Gyeonggi-do, KR;

Ji Hye Hwang, Gyeonggi-do, KR;

Young Nam Lee, Gyeonggi-do, KR;

Sang Myoung Noh, Gyeonggi-do, KR;

Min Hyo Ki, Gyeonggi-do, KR;

Assignee:

Chong Kun Dang Pharmaceutical Corp., Seoul, KR;

Attorneys:

Dentons US LLP

Stephanie Seidman

Primary Examiner:

Ileana Popa

Int. Cl.
CPC ...
A61K 9/00 (2006.01); A61K 47/00 (2006.01); A61K 48/00 (2006.01); A61K 9/19 (2006.01); A61K 31/722 (2006.01); A61K 9/127 (2006.01); C12N 15/11 (2006.01); A61K 9/14 (2006.01); A61K 31/7088 (2006.01); A61K 31/713 (2006.01); A61K 47/14 (2017.01); A61K 47/24 (2006.01); A61K 47/26 (2006.01); A61K 47/28 (2006.01); A61K 47/36 (2006.01); C12N 15/113 (2010.01);
U.S. Cl.
CPC ...
A61K 48/0041 (2013.01); A61K 9/0019 (2013.01); A61K 9/1274 (2013.01); A61K 9/14 (2013.01); A61K 9/19 (2013.01); A61K 31/7088 (2013.01); A61K 31/713 (2013.01); A61K 31/722 (2013.01); A61K 47/14 (2013.01); A61K 47/24 (2013.01); A61K 47/26 (2013.01); A61K 47/28 (2013.01); A61K 47/36 (2013.01); C12N 15/111 (2013.01); C12N 15/113 (2013.01); C12N 2310/11 (2013.01); C12N 2310/12 (2013.01); C12N 2310/14 (2013.01); C12N 2320/32 (2013.01);
Abstract

Disclosed herein is a composition for gene delivery which forms into liquid crystals in an aqueous fluid including chitosan and a liquid crystal formation material. The composition of the present invention including chitosan and a liquid crystal formation material improves the relatively low binding strength between chitosan and a gene, and also considerably increases the stability of a chitosan nanocomposite in blood serum, thereby performing highly efficient gene delivery and providing excellent stability, thus being useful as a gene therapeutic agent.

Find Patent Forward Citations

Loading…